144510.Kq
144510.KQ operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and sale of pharmaceutical products.
Business. 144510.KQ operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
144510.KQ operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development and sale of pharmaceutical products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.43, indicating a relatively conservative use of debt financing. However, the company's liquidity position is concerning, as evidenced by a negative cash and equivalents balance of -43,400 KRW and a current ratio of 0.46, which is below the industry median. This suggests that the company may face challenges in meeting its short-term obligations without external financing.
Profitability metrics are severely negative, with a return on equity of -1.4639 and a return on assets of -0.8985. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating income is significantly negative at -24,641,729,1890 KRW, and the net income is also negative at -27,285,886,6670 KRW, which is far below the industry median for profitability.
The company's revenue is concentrated in a single segment, as no additional segments are disclosed in the financial data. There is no information provided on geographic exposure, but the negative net cash position and high operating losses suggest that the company may be facing challenges in its primary market. The lack of diversification in revenue sources could increase the company's vulnerability to market fluctuations.
The company's growth trajectory is negative, with a significant decline in operating income and net income. The free cash flow is also negative at -264,526,320,310 KRW, indicating that the company is not generating sufficient cash from operations to fund its activities. The capital expenditure of -6,474,372,970 KRW further suggests that the company is not investing in growth opportunities.
The company faces significant liquidity risk, as indicated by the negative cash and equivalents balance and the current ratio below 1. The risk assessment also highlights the net cash being negative after subtracting total debt, which could lead to financial distress. The dilution risk is currently low, but the company's negative free cash flow and high debt levels could necessitate future equity issuances, which would increase dilution risk.
Recent events, as reflected in the financial data, include a substantial decline in profitability and liquidity. The company's operating cash flow is positive at 9,192,592,370 KRW, but this is not sufficient to offset the negative free cash flow. The company's financial health is deteriorating, and there are no recent filings or transcripts provided to indicate any strategic changes or improvements in the company's financial position.
- The company is experiencing significant financial distress, with negative operating and net income.
- The liquidity position is weak, with a negative cash balance and a current ratio below 1.
- The company's profitability metrics are far below industry medians, indicating poor performance.
- The company is not generating sufficient free cash flow to support its operations or growth.
- The risk assessment highlights liquidity and dilution risks, which could impact the company's financial stability.
- **margin_outlook_rationale**: The company's margins are expected to remain negative due to high operating losses and declining profitability.
- **rd_outlook_rationale**: There is no specific information provided on R&D spending, but the negative free cash flow suggests limited investment in research and development.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 144510.KQ Market data — financials · 2026-05-26